Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report

Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report

Abstract Background Gemcitabine and cisplatin are chemotherapeutic agents used for treating multiple cancers, and these agents are sometimes used in combination. Drug-induced thrombotic microangiopathy (TMA) is a rare but potentially fatal complication. It typically presents as a systemic disease wi...

Full description

Bibliographic Details
Main Authors: Masashi Nishikubo, Yoshimitsu Shimomura, Nobuhiro Hiramoto, Naohiko Sawamura, Takako Yamaguchi, Shigeo Hara, Takayuki Ishikawa
Format: Article
Language:English
Published: BMC 2021-05-01
Series:BMC Nephrology
Subjects:
Thrombotic microangiopathies
Gemcitabine
Cisplatin
Urinalysis
Lymphoma
Proteinuria
Online Access:https://doi.org/10.1186/s12882-021-02386-y

Internet

https://doi.org/10.1186/s12882-021-02386-y

Similar Items